Exscientia (EXAI) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exscientia in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EXAI shares.
View EXAI analyst ratings or view top-rated stocks.

3 equities research analysts have issued 12-month price objectives for Exscientia's shares. Their EXAI share price forecasts range from $12.00 to $14.00. On average, they expect the company's stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 151.5% from the stock's current price.
View analysts price targets for EXAI or view top-rated stocks among Wall Street analysts.

Exscientia's stock was trading at $5.33 on January 1st, 2023. Since then, EXAI stock has decreased by 3.0% and is now trading at $5.17.
View the best growth stocks for 2023 here.

Exscientia saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 2,280,000 shares, an increase of 13.4% from the August 15th total of 2,010,000 shares. Based on an average daily volume of 339,000 shares, the short-interest ratio is currently 6.7 days. Currently, 2.0% of the company's shares are sold short.
View Exscientia's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023.
View our EXAI earnings forecast.

Exscientia plc (NASDAQ:EXAI) posted its earnings results on Thursday, August, 10th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.04. The company earned $3.80 million during the quarter, compared to analysts' expectations of $16.27 million. Exscientia had a negative net margin of 685.82% and a negative trailing twelve-month return on equity of 31.67%.

ETFs with the largest weight of Exscientia (NASDAQ:EXAI) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

(EXAI) raised $291 million in an IPO on Friday, October 1st 2021. The company issued 13,850,000 shares at a price of $20.00-$22.00 per share.

Exscientia trades on the NASDAQ under the ticker symbol "EXAI."

Exscientia's stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (4.20%), Platinum Investment Management Ltd. (3.30%), Pivotal bioVenture Partners Investment Advisor LLC (0.64%), Woodline Partners LP (0.63%), BlackRock Inc. (0.57%) and Point72 Asset Management L.P. (0.48%).

Shares of EXAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EXAI stock can currently be purchased for approximately $5.17.

Exscientia (NASDAQ:EXAI) has a market capitalization of $625.00 million and generates $32.90 million in revenue each year. The company earns $-146,850,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis.

The company employs 481 workers across the globe.

The official website for the company is www.exscientia.ai. The company can be reached via phone at 44-0-18-6581-8941 or via email at investors@exscientia.ai.